Abemaciclib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Drug reference
conivaptan
Nonselective V1a receptor/V2 receptor Antagonist · Aquaretic
Nonselective V1a receptor/V2 receptor AntagonistAquaretic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AbemaciclibSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AlfentanilSevereDatabaseDDInter
- AmiodaroneSevereDatabaseDDInter
Mechanism
Conivaptan is a nonselective V1a receptor/V2 receptor antagonist (aquaretic). It increases renal free water excretion with little or no change in electrolyte excretion by blocking V2 receptors in the collecting ducts, which normally increase water permeability. It also blocks V1a receptors. It does not affect Na+ reabsorption and thus does not stimulate the tubuloglomerular feedback mechanism.
Indications
euvolemic hyponatremia (in hospitalized patients)hypervolemic hyponatremia (in hospitalized patients)Euvolemic hyponatremia due to Tumor-Associated Syndrome of Inappropriate Antidiuretic Hormone (used in combination with fluid restriction)
Dosing
- Adult
- 20–120 mg PO bid or 10–40 mg IV
Pharmacokinetics
Half-life
5 to 12 h (terminal elimination)
Protein binding
highly protein bound
Metabolism
metabolized via CYP3A
Excretion
partially excreted by the kidney
Contraindications
- hypovolemic hyponatremia
- anuria
- strong inhibitors of CYP3A4 (e.g., clarithromycin, ketoconazole)
- use with hypertonic saline
Side effects
Common
polyuriadehydrationhypotensiondizzinesspyrexiaincreased thirstxerostomiaGI adverse effectsheadacheshypokalemiahyperglycemia
Serious
- osmotic demyelination syndrome (due to too rapid correction of hyponatremia)
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Alfentanil
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Amiodarone
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: absorption, metabolism
Source: DDInter
Artemether
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Astemizole
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atorvastatin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Avanafil
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Fetal growth restriction
FOGSI · Obstetrics & Gynaecology · 2018
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Sjögren's syndrome
EULAR · Rheumatology · 2025
Ask House about conivaptan
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team